1	Adapting COVID-19 research infrastructure to capture influenza and
2	respiratory syncytial virus alongside SARS-CoV-2 in UK healthcare
3	workers winter 2022/23: Results of a pilot study in the SIREN cohort
4	Authors: Sarah Foulkes <sup>1¶*</sup> , Katie Munro <sup>1¶</sup> , Dominic Sparkes <sup>1</sup> , Jonathan Broad <sup>1</sup> , Naomi
5	Platt <sup>1</sup> , Anna Howells <sup>1</sup> , Omolola Akinbami <sup>1</sup> , Jameel Khawam <sup>1</sup> , Palak Joshi <sup>1</sup> , Sophie Russell <sup>1</sup> ,
6	Chris Norman <sup>2</sup> , Lesley Price <sup>3</sup> , Diane Corrigan <sup>4</sup> , Michelle Cole <sup>1</sup> , Jean Timelin <sup>1</sup> , Louise
7	Forster <sup>1</sup> , Katrina Slater <sup>1</sup> , Conall H Watson <sup>1</sup> , Nick Andrews <sup>1</sup> , Andre Charlett <sup>1</sup> , SIREN study
8	group^, Ana Atti <sup>1</sup> , Jasmin Islam <sup>1</sup> , Colin S Brown <sup>1</sup> , Jonathan Turner <sup>1</sup> , Susan Hopkins <sup>1</sup> ,
9	Victoria Hall <sup>1</sup>
10	<sup>¶</sup> These authors contributed equally to this work.
11	Affiliations:
12 13	1: United Kingdom Health Security Agency (UKHSA), 10 South Colonnade, Canary Wharf, London, United Kingdom, E14 4PU
14 15	2: Health and Care Research Wales, 5 15, Castlebridge, 19 Cowbridge Rd E, Cardiff CF11 9AB
16 17	3: Public Health Scotland, Meridian Court, 5 Cadogan Street, Glasgow, United Kingdom, G2 6QE
18 19	4: Health and Social Care in Northern Ireland (HSC), 12-22 Linenhall Street, Belfast, United Kingdom, BT2 8BS
20	
21	*Corresponding author
22	Email: Sarah.Foulkes@UKHSA.gov.uk
23	
24	Members of SIREN study group included in supplementary material
25	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 26 ABSTRACT

27 Introduction

28 The combination of patient illness and staff absence driven by seasonal viruses culminates

29 in annual "winter pressures" on UK healthcare systems and has been exacerbated by

30 COVID-19. In winter 2022/23 we ran a pilot study aiming to introduce multiplex testing to

31 determine the incidence and burden of SARS-CoV-2, influenza and respiratory syncytial

32 virus (RSV) in our cohort of UK healthcare workers (HCWs).

33 Methods

The pilot study was conducted from 28/11/2022-31/03/2023 within the SIREN prospective

35 cohort study. Participants completed fortnightly questionnaires, capturing symptoms and sick

36 leave, and multiplex PCR testing for SARS-CoV-2, influenza and RSV, regardless of

37 symptoms. PCR-positivity rates by virus were calculated over time, and viruses were

compared by symptoms and severity. Self-reported symptoms and associated sick leave

39 were described. Sick leave rates were compared by vaccination status and demographics.

40 Results

41 5,863 participants were included, 84.6% female, 70.3% ≥45-years, and 33.4% were nurses. PCR-positivity peaked in early December for all three viruses (4.6 positives per 100 tests 42 (95%CI 3.5, 5.7) SARS-CoV-2, 3.9 (95%CI 2.2, 5.6) influenza, 1.4 (95%CI 0.4, 2.4) RSV), 43 declining to <0.3/100 tests after January for influenza/RSV, and around 2.5/100 tests for 44 SARS-CoV-2. Over one-third of all infections were asymptomatic, and symptoms were 45 similar for all viruses. 1,368 (23.3%) participants reported taking sick leave, median 4 days 46 (range 1-59). Rates of sick leave were higher in participants with co-morbidities, working in 47 clinical settings, and who had not been vaccinated (COVID-19 booster or seasonal influenza 48 49 vaccine) versus those who had received neither vaccine (2.04 vs 1.41 sick days/100 days, 50 adjusted Incidence Rate Ratio 1.47 (95%CI 1.38, 1.56).

# 51 Conclusion

- 52 This pilot demonstrated the use of multiplex testing allowed better understanding of the
- 53 impact of seasonal respiratory viruses and respective vaccines on the HCW workforce. This
- 54 highlights the important information on asymptomatic infection and persisting levels of
- 55 SARS-CoV-2 infection.

- \_ •

- . .

### 72 INTRODUCTION

73 UK healthcare systems experience significant challenges each winter, due to the impact of seasonal surges in respiratory viruses, including influenza and respiratory syncytial virus 74 75 (RSV), which combined are often described as "winter pressures" (1, 2). Respiratory illness increases patient attendance but also causes significant staff absence, with respiratory 76 77 illness the second most common cause of sick leave within the NHS (3). Reduction in staff sickness absence and preventing nosocomial transmission are the rationale for the annual 78 NHS winter flu vaccine campaign for healthcare workers (HCW) and the prioritisation of 79 80 HCW for COVID-19 vaccine boosters (4, 5).

81 As a result of the pandemic, COVID-19 has been well characterised in relation to key 82 scientific and clinical questions including the role of antibodies as correlates of protection. rates of asymptomatic disease and real-world vaccine effectiveness (6-11). However, this is 83 84 not the case for the other principle seasonal viruses, influenza and RSV, where the focus 85 has been on symptomatic disease and in populations most at risk, including children and the elderly (12, 13). HCWs are an important population to study given the impact of respiratory 86 illnesses on the workforce and their high exposure (14, 15), offering insights into the natural 87 history, epidemiology and burden of influenza and RSV in working aged populations. 88

The SARS-CoV-2 Immunity and Reinfection Evaluation (SIREN) study is a prospective cohort study of HCWs across the UK, with participants completing regular SARS-CoV-2 PCR testing and antibody testing continuously since June 2020 (16). It was set up at the start of the pandemic to assess the risk of re-infection with SARS-CoV-2 and has continued to adapt to address key scientific questions.

During the COVID-19 pandemic, the introduction of non-pharmaceutical measures, including universal masking and social distancing, was found to reduce the rates of other respiratory viruses (4, 17). However, following the removal of these interventions, the winter of 2022/23 was the first opportunity to understand the impact of circulating seasonal viruses on the NHS

workforce. Therefore, in winter 2022/23 the SIREN study piloted a "Winter Pressures substudy" that included multiplex PCR testing for influenza and RSV alongside SARS-CoV-2
(18).

101 This paper outlines the results of the SIREN Winter Pressures Pilot study 2022/23, with the

aim of a) describing the burden of influenza (A and B), RSV, and SARS-CoV-2, b)

103 characterisation of SIREN HCW symptom profile, and c) understanding time off work due to

being symptomatic in the context of HCW vaccination.

105

# 106 METHODS

# 107 Study design

108 The SIREN Winter Pressures sub-study is a prospective cohort study nested within the 109 SIREN UK multicentre HCW cohort study (16, 18).

# 110 Participants

111 Participants were recruited into the sub-study via two routes: 1) participants previously

112 completing monoplex testing (for SARS-CoV-2 only) were informed, in writing, before the

sub-study start date (28 November 2022) that testing would move to multiplex testing

114 (SARS-CoV-2, Influenza and RSV), and were given the opportunity to withdraw from the

study; 2) additional participants were re-recruited (from participants who were not currently

testing) and consented directly into the winter pressures postal testing pathway, between 13

117 December 2022 and 24 January 2023 (18).

118 Participants undergoing PCR testing between 28 November 2022 and 31 March 2023 were

included in the sub-study. Participants contributed different lengths of time to the analysis

120 period, due to completing study follow-up time or withdrawing from the study.

121

## 123 Data collection

- 124 Participants completed fortnightly questionnaires on symptoms (onset date, type and
- duration) and related time taken-off work due to reported symptoms, in addition to an
- 126 enrolment survey at the start of the SIREN study, detailing the participant's demographics,
- 127 occupation, underlying medical conditions and household composition. Vaccination data
- 128 (COVID-19 and seasonal influenza vaccination) was obtained both from the fortnightly
- 129 questionnaire and linkage to national vaccination registries.
- 130 Participants completed swabs for either multiplex PCR (SARS-CoV-2, influenza and where
- available RSV) or monoplex PCR (SARS-CoV-2 only), fortnightly regardless of symptoms.
- 132 PCR testing, symptoms and sociodemographic data were linked via a unique study ID.

### 133 Variables

We defined participants who reported at least one of any of the following symptoms as being 134 symptomatic: cough, fever, shortness of breath, sore throat, runny nose, headache, muscle 135 136 aches, altered sense of smell or taste, fatigue, diarrhoea, nausea or vomiting, itchy red patches on fingers or toes, rash, swollen glands (19). Influenza-like illness (ILI) was defined 137 as participants reporting fever and at least one of following: cough, sore throat, shortness of 138 139 breath, headache, muscle ache or fatigue. For this analysis, COVID-19 vaccination refers to receiving the second booster dose of the COVID-19 vaccine, and influenza vaccination 140 141 refers to receiving the 2022/23 seasonal influenza vaccine between 01 September 2022 and 142 31 March 2023. Sick leave was defined as any self-reported days off work due to being symptomatic. 143

### 144 Outcomes

The co-primary outcomes were a) a PCR-positive test for either SARS-CoV-2, influenza or
RSV; b) proportion of participants reporting ILI symptoms; and c) the number of days taken
off work due to being symptomatic.

148

## 149 Inclusion criteria

- 150 Participants who completed at least one fortnightly questionnaire and at least one PCR test
- 151 during the analysis period were included.

## 152 Statistical analysis

- 153 Participants' sociodemographic and occupational characteristics were described.
- 154 Infection rates by pathogen were calculated over time. Samples were initially de-duplicated
- resulting in one test per fortnight per participant, prioritising a positive sample over a
- negative sample in the same fortnight. Samples which were positive for multiple viruses
- 157 were excluded from the analysis. Further de-duplication by infection episode meant that for
- 158 SARS-CoV-2, participants could only have one positive sample per 90 days. For influenza
- and RSV, participants could only have one positive sample per 30 days.
- 160 For the infection analysis, participants were considered vaccinated if they had received the
- 161 seasonal vaccine dose at least 14 days before the first positive PCR sample of the infection
- 162 episode.
- 163 An infection was considered symptomatic if the participant had reported a symptom onset
- date seven days pre or post the date of first positive PCR sample for each infection episode.
- 165 The proportion of participants with each infection was summarised by sociodemographic
- 166 characteristics and vaccination status. Symptom type, number, duration, hospital
- 167 attendance and time off work were compared by infection and vaccination status (SARS-
- 168 CoV-2 and influenza only) using proportions.

The proportion of participants reporting ILI symptoms was calculated over time, by dividing the number of surveys where ILI was reported by the total number of surveys in each time period.

Sick leave rate was calculated by fortnight, using the number of days taken off work dividedby the number of days participants contributed to the analysis period, per 100 days, with

95% confidence interval. Incidence rate ratio were calculated to estimate demographic
factors associated with taking time off work, unadjusted and adjusted (vaccination status,
age, occupational setting and co-morbidities).

177 For sick leave rate by vaccination status, participants contributed days to the vaccinated

state (COVID-19 and influenza separately or simultaneously) if they had received the

vaccine at least 14 days before the start of the fortnightly survey period. Participants

180 contributed days to the unvaccinated state if they had not received the seasonal dose or had

received the dose after the end of the survey period. For participants who received either

vaccine within a survey period, or within the 14 days prior to the survey start date, this

183 survey period did not count towards the rate analysis.

184

## 185 **RESULTS**

186 A total of 7,774 participants consented to the SIREN Winter Pressures pilot sub-study from

187 28 November 2022 to 31 March 2023. Of these, 5,863 (75.4%) participants had both survey

and testing data and were included in the analysis (Fig 1). Most participants were female

(84.6%), of white ethnicity (91.4%), over 45-years of age (70.3%); nursing was the largest

staff group (33.4%). Study participants were highly vaccinated, with 74.2% receiving both

191 COVID-19 and the seasonal influenza vaccine (Table 1).

192

Fig 1: Flow diagram describing participants included in the SIREN Winter Pressures
 pilot sub-study

195

196

#### Table 1: Demographics of participants included in the analysis, overall and by 198

#### infection (SARS-CoV-2, Influenza and RSV), 28 November 2022 to 31 March 2023 199

Characteriatia	All	SARS-CoV-2	Influenza	RSV
Characteristic	participants	positive	positive	positive
<b>T</b> . 4 . 1	<u>n (%)</u>	N (%)	n (%)	n (%)
Total	5,863	643	91	74
Age group		(s. s.)		
Under 25	39 (0.7)	1 (0.2)	1 (1.1)	3 (4.1)
25 to 34	447 (7.6)	56 (8.7)	11 (12.1)	2 (2.7)
35 to 44	1,257 (21.4)	151 (23.5)	24 (26.4)	13 (17.6)
45 to 54	2,280 (38.9)	244 (37.9)	30 (33.0)	36 (48.6)
55 to 64	1,690 (28.8)	173 (26.9)	23 (25.3)	20 (27.0)
Over 65	150 (2.6)	18 (2.8)	2 (2.2)	0 (0.0)
Gender				
Female	4,960 (84.6)	541 (84.1)	67 (73.6)	64 (86.5)
Male	896 (15.3)	101 (15.7)	24 (26.4)	9 (12.2)
Non-binary	4 (0.1)	1 (0.2)	0 (0.0)	1 (1.4)
Prefer not to say	3 (0.1)	0 (0.0)	0 (0.0)	0 (0.0)
Ethnicity				
White	5,359 (91.4)	594 (92.4)	85 (93.4)	70 (94.6)
Asian	272 (4.6)	30 (4.7)	4 (4.4)	3 (4.1)
Black	94 (1.6)	5 (0.8)	0 (0.0)	0 (0.0)
Mixed Race	70 (1.2)	6 (0.9)	1 (1.1)	1 (1.4)
Other Ethnic Group	52 (0.9)	4 (0.6)	1 (1.1)	0 (0.0)
Prefer not to say	16 (0.3)	4 (0.6)	0 (0.0)	0 (0.0)
Medical condition				
Chronic respiratory conditions	738 (12.6)	75 (11.7)	13 (14.3)	8 (10.8)
Chronic non-respiratory	679 (11.6)	76 (11.8)	8 (8.8)	13 (17.6)
conditions		- 1 - 7	- ( /	- ( - )
Immunosuppression	128 (2.2)	16 (2.5)	2 (2.2)	1 (1.4)
No medical condition	4,318 (73.6)	476 (74.0)	68 (74.7)	52 (70.3)
Household				
Lives alone	683 (11.6)	82 (12.8)	11 (12.1)	9 (12.2)
Lives with adults	3,010 (51.3)	325 (50.5)	42 (46.2)	30 (40.5)
Lives with children	2,170 (37.0)	236 (36.7)	38 (41.8)	35 (47.3)
Staff type	_,	100 (000)/	00 ( 1210)	00 ( 11 10)
Nursing	1,957 (33.4)	221 (34.4)	22 (24.2)	21 (28.4)
Administrative/Executive	1,014 (17.3)	95 (14.8)	14 (15.4)	11 (14.9)
Doctor	670 (11.4)	67 (10.4)	12 (13.2)	14 (18.9)
Healthcare Assistant	360 (6.1)	53 (8.2)	3 (3.3)	2 (2.7)
Healthcare Scientist	279 (4.8)		1 2	1 /
Student	279 (4.8) 175 (3.0)	32 (5.0) 25 (3.9)	7 (7.7) 3 (3.3)	5 (6.8) 1 (1.4)
Physiotherapist/Occupational				
Therapist/SALT	228 (3.9)	33 (5.1)	10 (11.0)	4 (5.4)
Midwife	133 (2.3)	12 (1.9)	3 (3.3)	1 (1.4)
Pharmacist	129 (2.2)			
Estates/Porters/Security	129 (2.2) 113 (1.9)	16 (2.5) 8 (1.2)	3 (3.3) 3 (3.3)	2 (2.7)
Other	805 (13.7)			1 (1.4)
	000(10.7)	81 (12.6)	11 (12.1)	12 (16.2)
Occupation setting	4 000 (00 7)	125 /21 21	26/22 61	44 14 4 -1
Office	1,333 (22.7)	135 (21.0)	26 (28.6)	11 (14.9)
Outpatient	1,213 (20.7)	135 (21.0)	19 (20.9)	18 (24.3)
Inpatient Wards	671 (11.4)	89 (13.8)	9 (9.9)	13 (17.6)
Patient facing (non-clinical)	273 (4.7)	29 (4.5)	2 (2.2)	8 (10.8)
Intensive Care	208 (3.5)	30 (4.7)	4 (4.4)	4 (5.4)
Theatres	152 (2.6)	22 (3.4)	2 (2.2)	5 (6.8)
Ambulance/Emergency	108 (1.8)	12 (1.9)	4 (4.4)	2 (2.7)
Department	<b>00</b> (1 1)	- 4.		
Maternity/Labour Ward	82 (1.4)	7 (1.1)	1 (1.1)	1 (1.4)
Other	1,823 (31.1)	184 (28.6)	24 (26.4)	12 (16.2)

Characteristic	All participants n (%)	SARS-CoV-2 positive N (%)	Influenza positive n (%)	RSV positive n (%)
Patient contact				
Yes	4,841 (82.6)	535 (83.2)	75 (82.4)	71 (95.9)
No	1,022 (17.4)	108 (16.8)	16 (17.6)	3 (4.1)
Vaccination status				
Both	4,349 (74.2)	481 (74.8)	62 (68.1)	54 (73.0)
Influenza 2022/23 vaccine only	499 (8.5)	53 (8.2)	8 (8.8)	5 (6.8)
COVID-19 second booster	354 (6.0)	28 (4.4)	10 (11.0)	5 (6.8)
dose only				
Neither	661 (11.3)	81 (12.6)	11 (12.1)	10 (13.5)

200 Note: Eight participants had multiple infections during the analysis period – four participants had a SARS-CoV-2

201 and an influenza infection, three had influenza and RSV, and one had SARS-CoV-2 and RSV.

202

#### SARS-CoV-2, influenza and RSV infection rates over winter 2022/23 203

All 5,863 participants were tested for SARS-CoV-2, 4,689 (80.0%) for influenza and 4,695 204

(80.0%) for RSV. Of these, 643/5,863 (11.0%) participants had a positive SARS-CoV-2 205

206 result, 93/4,689 (2.0%) had a positive influenza result and 74/4,695 (1.6%) had a positive

- RSV result. 207
- PCR positivity rates for all three viruses peaked in early December 2022 (peak positive PCR 208
- per 100 tests: 4.6 (95% CI 3.5, 5.7) for SARS-CoV-2, 3.9 (95% CI 2.2, 5.6) influenza, 1.4 209
- (95% CI 0.4, 2.4) RSV), with influenza and RSV decreasing to low levels after January 2023 210
- 211 (for influenza ≤0.2 and RSV ≤0.3 positives per 100 tests), whereas SARS-CoV-2 maintained
- rates around 2.5 per 100 tests until March 2023 (Fi 2). 212
- 213

Fig 2: PCR positivity rate (per 100 tests) by fortnight and infection, 28 November 2022 214 to 31 March 2023 215

- 216 Note: shaded areas represent 95% confidence intervals
- 217

218

# 220 Influenza-like illness symptoms over winter 2022/23

- There were 4,003 (68.3%) participants who reported symptoms over the analysis period,
- with 1,054 (18.0%) reporting ILI symptoms. The proportion of participants reporting ILI
- symptoms by fortnight peaked in early December 2022 (peak fortnight was 7.5% (95% CI
- 224 6.8, 8.3) (368/4,893 surveys) (Fig 3).
- 225
- Fig 3: Proportion of participants reporting influenza-like illness symptoms by
- 227 fortnight, 28 November 2022 to 31 March 2023
- 228 Shaded areas represent 95% confidence intervals
- 229

# 230 Symptom profile by SARS-CoV-2, influenza and RSV

- The proportion of asymptomatic infections were similar among the three viruses influenza
- (45.6%), SARS-CoV-2 (41.7%) and RSV (37.5%). Symptom profiles were similar for all three
- viruses. Although, loss of sense of smell and taste were more common among those with an
- 234 SARS-CoV-2 infection and fever more common with a influenza infection. Hospital
- attendance was low for all viruses (Table 2).

236

- 238
- 239
- 240
- 241

#### 242 Table 2: Description of the symptom profile and severity of SARS-CoV-2, influenza

#### and RSV PCR positive infections, 28 November 2022 to 31 March 2023 243

	SARS-CoV-2 n (%)	Influenza n (%)	RSV n (%)	<b>p-value</b> (SARS- CoV-2 vs influenza)	<b>p-value</b> (SARS-CoV-2 vs RSV)	<b>p-value</b> (RSV vs influenza)
Total	643	93	74			
Symptoms				0.494	0.594	0.327
Any symptoms	346 (58.3)	49 (54.4)	40 (62.5)			
Asymptomatic	247 (41.7)	41 (45.6)	24 (37.5)			
Symptoms type						
Loss of smell	67 (11.3)	3 (3.3)	4 (6.3)	0.015	0.289	0.45
Cough	182 (30.7)	33 (36.7)	17 (26.6)	0.274	0.568	0.223
Diarrhoea	37 (6.2)	5 (5.6)	2 (3.1)	>0.999	0.414	0.7
Loss of taste	80 (13.5)	3 (3.3)	4 (6.3)	0.005	0.116	0.45
Fatigue	160 (27.0)	24 (26.7)	13 (20.3)	>0.999	0.297	0.445
Fever	105 (17.7)	25 (27.8)	9 (14.1)	0.03	0.602	0.05
Swollen glands	45 (7.6)	6 (6.7)	1 (1.6)	>0.999	0.074	0.24
Headache	228 (38.4)	29 (32.2)	24 (37.5)	0.294	>0.999	0.606
Muscle aches	179 (30.2)	24 (26.7)	13 (20.3)	0.538	0.112	0.445
Runny nose	258 (43.5)	33 (36.7)	28 (43.8)	0.253	>0.999	0.406
Shortness of breath	87 (14.7)	12 (13.3)	13 (20.3)	0.873	0.27	0.273
Sore throat	231 (39.0)	39 (43.3)	29 (45.3)	0.488	0.348	0.87
Vomiting	38 (6.4)	8 (8.9)	5 (7.8)	0.368	0.598	>0.999
Duration of symptoms	, <i>t</i>	, <i>t</i>	<b>, , , , , , , , , , , , , , , , </b>	0.09	0.405	0.729
1-3	43 (12.6)	1 (2.0)	2 (5.0)			
4-6	79 (23.2)	10 (20.4)	8 (20.0)			
7-14	54 (15.9)	8 (16.3)	9 (22.5)			
>14	164 (48.2)	30 (61.2)	21 (52.5)			
Sick leave				0.002	0.868	0.049
Taken	180 (52.2)	14 (28.6)	20 (50.0)			
Not taken	165 (47.8)	35 (71.4)	20 (50.0)	0.045	0.404	0.070
Number of sick leave ta		0 (04.0)	10 (50 0)	0.015	0.484	0.079
1-3 4-6	67 (37.2) 56 (31.1)	9 (64.3) 5 (35.7)	10 (50.0) 4 (20.0)			
4-0 7-14	57 (31.7)	0 (0.0)	4 (20.0) 6 (30.0)			
Hospital attendance	01 (01.1)	0 (0.0)	0 (00.0)	0.358	0.095	0.654
Yes	8 (2.3)	2 (4.1)	3 (7.5)	0.000	0.000	0.001
No	338 (97.7)	47 (95.9)	37 (92.5)			

244 245

#### Time off work due to being symptomatic over winter 2022/23 246

Of participants testing positive for SARS-CoV-2 and RSV, ≥50% of participants reported 247

taking time off work for being symptomatic (52.2% and 50.0%, respectively), compared to 248

249 28.6% for influenza infections (Table 2). The median number of days taken off work for a

SARS-CoV-2 infection was 5 (IQR: 2-7); 3 days (IQR: 2.25-5) for influenza and 4 days (IQR: 250

2-7) for RSV. 251

252 Over the analysis period, a total of 1,368/5,863 (23.3%) participants reported taking time off

- work due to being symptomatic; taking a median of 4 days off over the analysis period
- (range: 1-59 days). Of participants reporting ILI symptoms, 616/1,054 (58.4%) reported
- taking time off work; taking a median of 5 days; range: 1-59 days.
- The 5,863 participants included contributed to a total of 507,388 follow-up days during the
- winter period. The rate of sick leave over this period was 1.48 days per 100 days of follow-
- up, with the peak seen in early December 2022 (2.4 days per 100 days) (Fig 4).

259

```
Fig 4: Rate of sick leave taken (per 100 days) by fortnight, 28 November 2022 to 31
```

- 261 March 2023
- 262 Note: Sick leave rate was calculated as number of sick leave days taken divided by the
- number of days participants contributed to the analysis period, per 100 days; Shaded areas
- 264 represent 95% confidence intervals
- 265

## 266 Factors associated with taking time off work

- 267 Participants who took time off work due to being symptomatic between November 2022 and
- March 2023 appeared to differ by occupational setting, long-term medical conditions and
- 269 vaccination status (Table 3).

### Table 3: Factors associated with time off work due to being symptomatic, 28

### 271 November 2022 to 31 March 2023

Characteristic	Sick leave rate <sup>b</sup> (95% Cl)	IRR (95% CI)	Adjusted IRR (95% CI)	
Vaccination status <sup>a</sup>				
Both COVID-19 second booster and Influenza 2022/23 vaccine	1.41 (1.37, 1.45)	Ref	Ref	
Influenza 2022/23 Vaccine	1.52 (1.40, 1.65)	1.08 (0.99, 1.17)	1.04 (0.95, 1.13)	
COVID-19 second booster dose	1.26 (1.14, 1.40)	0.90 (0.81, 10)	0.91 (0.82, 1.02)	
Neither vaccine	2.04 (1.93, 2.16)	1.45 (1.36, 1.54)	1.47 (1.38, 1.56)	

Age group			
Under 25	1.55 (1.10, 2.16)	Ref	Ref
25 to 34	1.84 (1.69, 1.99)	1.19 (0.85, 1.66)	1.16 (0.83, 1.63)
35 to 44	1.51 (1.44, 1.59)	0.98 (0.70, 1.36)	0.92 (0.66, 1.28)
45 to 54	1.49 (1.43, 1.54)	0.96 (0.69, 1.33)	0.91 (0.65, 1.26)
55 to 64	1.44 (1.38, 1.50)	0.93 (0.67, 1.29)	0.89 (0.64, 1.24)
Over 65	0.69 (0.56, 0.84)	0.44 (0.30, 0.65)	0.45 (0.30, 0.66)
Occupation setting			
Theatres	2.13 (1.89, 2.40)	1.91 (1.68, 2.18)	1.89 (1.66, 2.15)
Intensive Care	1.91 (1.72, 2.13)	1.72 (1.52, 1.94)	1.74 (1.54, 1.96)
Outpatient	1.62 (1.55, 1.70)	1.45 (1.35, 1.56)	1.49 (1.39, 1.60)
Ambulance/Emergency Department	1.58 (1.33, 1.86)	1.42 (1.19, 1.69)	1.36 (1.14, 1.62)
Maternity/Labour Ward	1.58 (1.30, 1.92)	1.42 (1.16, 1.73)	1.38 (1.13, 1.68)
Inpatient Wards	1.57 (1.47, 1.67)	1.41 (1.29, 1.53)	1.36 (1.25, 1.49)
Patient facing (non-clinical)	1.53 (1.38, 1.70)	1.38 (1.23, 1.55)	1.40 (1.25, 1.57)
Other	1.50 (1.44, 1.56)	1.35 (1.26, 1.44)	1.38 (1.29, 1.47)
Office	1.11 (1.05, 1.18)	Ref	Ret
Medical group			
No medical condition	1.29 (1.26, 1.33)	Ref	Re
Immunosuppression	2.71 (2.42, 3.03)	2.09 (1.86, 2.35)	2.19 (1.95, 2.46)
Chronic Respiratory conditions	2.01 (1.90, 2.12)	1.55 (1.46, 1.65)	1.60 (1.50, 1.70
Chronic Non-Respiratory conditions	1.87 (1.77, 1.99)	1.45 (1.36, 1.55)	1.52 (1.42, 1.63)

272 <sup>a</sup> Participants were excluded if they were vaccinated in one survey period and unvaccinated in another survey

273 period. Surveys were excluded from the analysis if the participant was vaccinated within the survey date range.<sup>b</sup>

274 Sick leave rate was calculated as number of sick leave days taken divided by the number of days participants

275 contributed to the analysis period, per 100 days. IRR = Incidence rate ratio. CI = Confidence interval

277	Participants in office-based roles took less time off work (1.11 days per 100 days) when
278	compared to clinical roles such as theatres and intensive care units (2.13 and 1.91 days per
279	100 days, respectively. Estimated from adjusted Incidence Rate Ratios (IRR) also show this;
280	theatres (1.89; 95% CI 1.66, 2.15) and intensive care units (1.74; 95% CI 1.54, 1.96) verses
281	office-based participants. Participants with immunosuppressive, chronic respiratory and
282	chronic non-respiratory conditions took more time off work than participants with no reported
283	comorbidities (who took off 1.29 days per 100 days): immunosuppressive conditions 2.71
284	days per 100, adjusted IRR 2.19 (95% CI 1.95, 12.46); chronic respiratory 2.01/100 days,

adjusted IRR 1.60 (95% CI 1.50, 1.70); and chronic non-respiratory conditions 1.87/100
days, adjusted IRR 1.52 (95% CI 1.42, 1.63).

Those who were vaccinated against both influenza and COVID-19 took less time off work (1.41 days per 100 days) than those who did not receive either vaccine (2.04 days per 100 days) (Table 3). After controlling for age, occupational setting and co-morbidities, we estimated that those who received neither vaccine had a 47% higher rate of sick leave than those vaccinated for both (adjusted IRR 1.47 (95% CI 1.38, 1.56)).

292

## 293 DISCUSSION

Results from the 2022/23 SIREN Winter Pressures pilot study demonstrate the impact of respiratory illness on the NHS workforce. Rates of SARS-CoV-2, influenza and RSV, and symptoms, all peaked in early December, resulting in increased levels of sickness absence over this time period.

298 The PCR positivity trends over winter 2022/23 in our cohort of HCW is consistent with national surveillance data (17) demonstrating the potential utility of conducting surveillance in this 299 population to determine the prevalence and impact of respiratory viral infections in the working 300 301 age population (20). Our detection of RSV infections in this population, which is rarely tested for this virus, suggests that RSV also contributes to winter pressures. The finding that 302 303 symptom profiles were similar across the three viruses is consistent with existing published literature (21). Across all three viruses, a substantial proportion of infections were 304 asymptomatic but could potentially contribute to transmission, in particular, influenza with over 305 two-thirds of infections asymptomatic (22). This highlights the potential risk associated with 306 307 nosocomial infections in healthcare workers, though we do not have strong evidence how 308 transmissible asymptomatic infections is. The impact of respiratory illness on time off work in 309 our cohort of HCW over winter 2022/23 was considerable, with 23% of participants reporting time off work due to being symptomatic, and all three viruses contributing to this. Sick leave 310

rates varied by demographics and vaccination status, with lower estimated rates among those
who received the second COVID-19 booster and seasonal influenza vaccine. Given the impact
that HCW time off work could have on healthcare resilience over winter, further research into
associated factors, including behaviours and attitudes, is important.

A key limitation of this pilot study was the coverage and timing of multiplex PCR roll-out. There 315 were fewer participants with PCR results for influenza and RSV than those with a SARS-CoV-2 316 test result. In this pilot, multiplex testing was introduced late in the winter season, with testing 317 data only available from late November 2022, due to delays switching PCR platforms across 318 319 NHS laboratories (using a decentralised study testing model), and the timing of establishing a new centralised postal PCR pathway. This delay was compounded by an unusually early 320 influenza season in 2022/23 (17). Consequently, our surveillance of these viruses over winter 321 2022/23 may have missed some infections within our cohort, particularly influenza and RSV. 322

323 This pilot sub-study conducted during winter 2022/23 has demonstrated the adaptability and 324 applicability of findings from the SIREN HCW cohort. Results from the study show the benefit of regular multiplex testing across NHS Trusts to understand the interplay and impact 325 of seasonal viruses on workforce planning, patient care and healthcare resilience in the NHS 326 during the Winter. We have demonstrated that all three viruses contribute to staff illness and 327 328 time off work over winter, and that seasonal flu and COVID-19 vaccines were associated 329 with lower sick leave rates. Future studies should consider using a centralised multiplex 330 testing pathway to improve surveillance of respiratory infections and ensure the timing of 331 testing is optimised.

- 332
- 333
- 334

## 336 ACKNOWLEDGEMENTS

337 Our thanks go to the participants in the SIREN study. We would also like to thank the help

and support offered by the Berkshire Research Ethics Committee and the HDR-UK for winter

pressures funding and to UKHSA for core SIREN study funding. Thanks also to all research

- team and site staff not mentioned above.
- 341

### 342 **REFERENCES**

1. Elliot AJ, Cross KW, Fleming DM. Acute respiratory infections and winter pressures

on hospital admissions in England and Wales 1990-2005. J Public Health (Oxf).

345 2008;30(1):91-8.

346 2. Mahase E. NHS England announces "data driven war rooms" to tackle winter

347 pressures. BMJ. 2022;379:o2515.

348 3. NHS Sickness Absence Interactive Dashboard [Internet]. 2024 [cited 06/02/2024].

349 Available from:

350 https://app.powerbi.com/view?r=eyJrljoiYTY3MjE0NmEtYzY2Yi00MmY4LTg4NDQtZTM2ZTI

351 <u>5YjZiOGMyliwidCl6ljUwZjYwNzFmLWJiZmUtNDAxYS04ODAzLTY3Mzc0OGU2MjllMilsImM</u>

352 <u>iOjh9</u>.

UKHSA. Influenza: the green book, chapter 19. In: UKHSA, editor. The Green Book.
 gov.uk2023. p. 18.

355 5. UKHSA. Immunisation of healthcare and laboratory staff: the green book, chapter 12.
356 In: UKHSA, editor. The Green Book. gov.uk: UKHSA; 2013. p. 1-8.

357 6. Atti A, Insalata F, Carr EJ, Otter AD, Foulkes S, Wu MY, et al. Antibody correlates of

358 protection against Delta infection after vaccination: A nested case-control within the UK-

359 based SIREN study. J Infect. 2023;87(5):420-7.

360 7. Regev-Yochay G, Lustig Y, Joseph G, Gilboa M, Barda N, Gens I, et al. Correlates of

361 protection against COVID-19 infection and intensity of symptomatic disease in vaccinated

individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort
 study. Lancet Microbe. 2023;4(5):e309-e18.

8. Ma Q, Liu J, Liu Q, Kang L, Liu R, Jing W, et al. Global Percentage of Asymptomatic

365 SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed

366 COVID-19 Diagnosis: A Systematic Review and Meta-analysis. JAMA Netw Open.

367 2021;4(12):e2137257.

368 9. Hall V, Foulkes S, Insalata F, Saei A, Kirwan P, Atti A, et al. Effectiveness and

369 durability of protection against future SARS-CoV-2 infection conferred by COVID-19

370 vaccination and previous infection; findings from the UK SIREN prospective cohort study of

371 healthcare workers March 2020 to September 2021. medRxiv. 2021:2021.11.29.21267006.

10. Kirwan PD, Hall VJ, Foulkes S, Otter AD, Munro K, Sparkes D, et al. Effect of second

373 booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare

worker cohort. Lancet Reg Health Eur. 2024;36:100809.

11. Huiberts AJ, de Gier B, Hoeve CE, de Melker HE, Hahne SJ, den Hartog G, et al.

376 Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection,

the Netherlands, September to December 2022. Euro Surveill. 2023;28(7).

12. Riccio MD, Spreeuwenberg P, Osei-Yeboah R, Johannesen CK, Fernandez LV,

379 Teirlinck AC, et al. Defining the Burden of Disease of RSV in Europe: estimates of RSV-

associated hospitalisations in children under 5 years of age. A systematic review and


381 modelling study. medRxiv. 2023:2023.02.10.23285756.


13. Coultas JA, Smyth R, Openshaw PJ. Respiratory syncytial virus (RSV): a scourge
from infancy to old age. Thorax. 2019;74(10):986-93.


14. Vargese SS, Dev SS, Soman AS, Kurian N, Varghese VA, Mathew E. Exposure risk
and COVID-19 infection among frontline health-care workers: A single tertiary care centre
experience. Clin Epidemiol Glob Health. 2022;13:100933.

Macintyre CR, Seale H, Yang P, Zhang Y, Shi W, Almatroudi A, et al. Quantifying the
risk of respiratory infection in healthcare workers performing high-risk procedures. Epidemiol
Infect. 2014;142(9):1802-8.

390 16. Wallace S, Hall V, Charlett A, Kirwan PD, Cole M, Gillson N, et al. Impact of prior SARS-CoV-2 infection and COVID-19 vaccination on the subsequent incidence of COVID-391 19: a multicentre prospective cohort study among UK healthcare workers - the SIREN 392 (Sarscov2 Immunity & REinfection EvaluatioN) study protocol. BMJ Open. 393 394 2022;12(6):e054336. UKHSA. National Influenza and COVID-19 surveillance report. .gov.uk; 2023. 395 17. 396 18. Broad J, Sparkes D, Platt N, Howells A, Foulkes S, Khawam J, et al. Adapting 397 COVID-19 research infrastructure to capture influenza and respiratory syncytial virus 398 alongside SARS-CoV-2 in UK healthcare workers winter 2022/23 and beyond: protocol for a 399 pragmatic sub-study [version 1; peer review: awaiting peer review]. NIHR Open Research. 400 2024;4(1). 19. UKHSA, SIREN Follow-up Questionnaire v6.1, 2022. 401 402 20. Foulkes S, Monk EJM, Sparkes D, Hettiarachchi N, Milligan ID, Munro K, et al. Early Warning Surveillance for SARS-CoV-2 Omicron Variants, United Kingdom, November 2021-403 404 September 2022. Emerg Infect Dis. 2023;29(1):184-8. 405 21. Ma X, Conrad T, Alchikh M, Reiche J, Schweiger B, Rath B. Can we distinguish 406 respiratory viral infections based on clinical features? A prospective pediatric cohort compared to systematic literature review. Rev Med Virol. 2018;28(5):e1997. 407 22. Cohen C, Kleynhans J, Moyes J, McMorrow ML, Treurnicht FK, Hellferscee O, et al. 408 Asymptomatic transmission and high community burden of seasonal influenza in an urban 409 and a rural community in South Africa, 2017-18 (PHIRST): a population cohort study. Lancet 410 Glob Health. 2021;9(6):e863-e74. 411 412










Figure2

